Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Cybin Inc
(NY:
CYBN
)
0.3200
+0.0302 (+10.42%)
Official Closing Price
Updated: 8:00 PM EDT, Jul 12, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Cybin Inc
< Previous
1
2
3
4
5
6
7
8
9
...
16
17
Next >
Cybin Announces up to US$64 Million Offering of Units
November 10, 2023
From
Cybin Inc.
Via
Business Wire
InvestorNewsBreaks – Cybin Inc.’s (NEO: CYBN) (NYSE American: CYBN) Announces Participation at Upcoming Milken Institute Future of Health Summit
November 03, 2023
Via
Investor Brand Network
Cybin to Participate at the 2023 Milken Institute Future of Health Summit
November 03, 2023
From
Cybin Inc.
Via
Business Wire
InvestorNewsBreaks – Cybin Inc.’s (NEO: CYBN) (NYSE American: CYBN) Releases Update, Notes Upcoming Pipeline Milestones
November 01, 2023
Via
Investor Brand Network
Cybin Provides Corporate Update and Highlights Key Upcoming Milestones Across its Development Pipeline
November 01, 2023
From
Cybin Inc.
Via
Business Wire
Cybin Announces Unprecedented Positive Phase 2 Interim Data for CYB003 in Major Depressive Disorder Meeting Primary Efficacy Endpoint with Rapid and Significant Improvements in Depression Symptoms After Single Dose
October 31, 2023
From
Cybin Inc.
Via
Business Wire
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Expands Portfolio to Secure New European Patent
October 26, 2023
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Cybin Announces Grant of European Patent Protecting its Proprietary Deuterated Programs
October 26, 2023
From
Cybin Inc.
Via
Business Wire
InvestorNewsBreaks – Cybin Inc.’s (NEO: CYBN) (NYSE American: CYBN) Granted Two US Patents Protecting Exclusive Deuterated DMT Program
October 25, 2023
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Cybin Announces Grant of Two New United States Patents Protecting its Deuterated DMT Program
October 25, 2023
From
Cybin Inc.
Via
Business Wire
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Completes Strategic Acquisition, Poised as Leader in Psychedelics Sector
October 23, 2023
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Cybin Completes Acquisition of Small Pharma Inc. to Create International Clinical-stage Leader in Novel Psychedelic Therapeutics
October 23, 2023
From
Cybin Inc.
Via
Business Wire
Small Pharma Obtains Final Order Approving Arrangement
October 17, 2023
From
Cybin Inc.
Via
Business Wire
InvestorNewsBreaks – Cybin Inc.’s (NEO: CYBN) (NYSE American: CYBN) Reports on Voting Results from Annual Shareholder Meeting
October 13, 2023
Via
Investor Brand Network
Cybin Announces Results of Annual and Special Meeting of Shareholders
October 12, 2023
From
Cybin Inc.
Via
Business Wire
InvestorNewsBreaks – Cybin Inc.’s (NEO: CYBN) (NYSE American: CYBN) Abstract Selected for Presentation at Sixth Annual Neuropsychiatric Drug Development Summit
October 06, 2023
Via
Investor Brand Network
Cybin to Present an Abstract and Moderate a Psychedelic Workshop at the 6th Annual Neuropsychiatric Drug Development Summit
October 06, 2023
From
Cybin Inc.
Via
Business Wire
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) CEO to Present at Jefferies Inaugural Biotech CNS/Neuro Summit
October 04, 2023
Via
Investor Brand Network
Cybin to Present at the Jefferies Inaugural Biotech CNS/Neuro Summit
October 04, 2023
From
Cybin Inc.
Via
Business Wire
InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Wraps Up Phase 2 Study Dosing for Final Cohort
October 03, 2023
Via
Investor Brand Network
Cybin Completes Dosing in Phase 2 Study of CYB003 for the Treatment of Major Depressive Disorder
October 03, 2023
From
Cybin Inc.
Via
Business Wire
InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Notes Positive Top-Line Data Gathered from Small Pharma Study
September 27, 2023
Via
Investor Brand Network
Small Pharma Reports Positive Top-line Data from SPL026 (DMT)-SSRI Drug Interaction Study in Patients with Major Depressive Disorder
September 27, 2023
From
Cybin Inc.
Via
Business Wire
Cybin Announces Agreement with Fluence to Support Scaling of EMBARK Training for CYB003 Phase 3 Trial
September 26, 2023
From
Cybin Inc.
Via
Business Wire
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Participation in Cantor Global Healthcare Conference
September 25, 2023
Via
Investor Brand Network
Cybin to Participate in the Cantor Global Healthcare Conference
September 25, 2023
From
Cybin Inc.
Via
Business Wire
InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Schedules Annual Shareholder Meeting
September 22, 2023
Via
Investor Brand Network
Cybin Announces Date of Annual and Special Meeting of Shareholders
September 21, 2023
From
Cybin Inc.
Via
Business Wire
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Completes Enrollment in Phase 2 CYB003 Study
September 21, 2023
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Cybin Completes Enrollment in Phase 2 Study of CYB003 in Major Depressive Disorder
September 21, 2023
From
Cybin Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
...
16
17
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.